

Ref: MHL/Sec&Legal/2020-21/171

Date: February 10, 2021

To,  
**Head, Listing Compliance Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai - 400 001.

**Scrip Code: 542650**

**Head, Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051.  
**Scrip Symbol: METROPOLIS**

**Sub: Outcome of Board Meeting held on Wednesday, February 10, 2021**

**Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR')**

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held today have *inter-alia*:

- i. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020.

The copy of the Unaudited Standalone & Consolidated Financial Statements of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2020 is enclosed as **Annexure – 1**.

- ii. Approved the re-appointment of Ms. Ameera Sushil Shah as the Managing Director, for a period of five years with effect from March 18, 2021, as per the recommendation of the Nomination and Remuneration Committee, subject to approval of members of the Company at the ensuing Annual General Meeting.

The necessary details as required pursuant to Regulation 30 of SEBI LODR read with SEBI Circular CIR/CFD/CMD/4/2015 are enclosed as **Annexure – 2**.

- iii. Approved and declared payment of Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per equity share on the Face Value Rs. 2 (Rupees Two only) each for the financial year 2020-2021. The interim dividend will be paid to the members whose names appear in the Register of Members / Register of beneficiaries as on the 'Record Date' i.e. February 19, 2021. The Interim Dividend will be paid to the shareholders within 30 days of declaration.

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**

**METROPOLIS**  
The Pathology Specialist

**Metropolis Healthcare Limited**

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)

Website: [www.metropolisindia.com](http://www.metropolisindia.com)

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

- iv. Approved the change in constitution of the Nomination and Remuneration Committee of the Company with effect from February 10, 2021. The details of change in the Committee constitution is enclosed as **Annexure – 3**.

The meeting commenced at 2:00 p.m. and concluded at 4:10 p.m.

Thanking you,  
Yours faithfully

For **Metropolis Healthcare Limited**



Poonam Tanwani  
**Company Secretary & Compliance Officer**  
Membership No. A19182  
Encl. a/a

## BLOOD TESTS • DIAGNOSTICS • WELLNESS



### Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)

Website: [www.metropolisindia.com](http://www.metropolisindia.com)

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

# B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,  
Nesco IT Park 4, Nesco Center,  
Western Express Highway,  
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000  
Fax: +91 22 6257 1010

## Limited review report on unaudited quarterly and year-to-date standalone financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

### To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited ('the Company') for the quarter ended 31 December 2020 and year to date results for the period from 1 April 2020 to 31 December 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

TARUN K  
KINGER

Digitally signed by  
TARUN K KINGER  
Date: 2021.02.10  
14:37:53 +05'30'

Tarun Kinger  
Partner

Mumbai

10 February 2021

Membership No: 105003

ICAI UDIN: 21105003AAAAAQ9052

Registered Office:

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070

Statement of Standalone Financial Results for the quarter and nine month ended 31 December, 2020

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine month ended		Year ended
		31 December 2020 (Unaudited)	30 September 2020 (Unaudited)	31 December 2019 (Unaudited)	31 December 2020 (Unaudited)	31 December 2019 (Unaudited)	31 March 2020 (Audited)
1	<b>Income</b>						
	a) Revenue from operations	22,442.73	24,254.67	17,290.97	57,775.14	50,215.19	66,530.71
	b) Other income	236.57	182.56	178.49	656.52	359.67	2,931.79
	<b>Total Income</b>	<b>22,679.30</b>	<b>24,437.23</b>	<b>17,469.46</b>	<b>58,431.66</b>	<b>50,574.86</b>	<b>69,462.50</b>
2	<b>Expenses</b>						
	a) Cost of material consumed	5,896.91	6,415.54	4,264.67	15,474.11	12,478.97	16,724.71
	b) Laboratory testing charges	193.30	197.22	128.89	426.37	437.98	649.76
	c) Employee benefits expense	4,156.78	3,843.20	3,806.30	11,616.25	11,272.72	14,766.62
	d) Finance costs	122.45	125.73	183.64	380.88	496.20	656.01
	e) Depreciation and amortisation expense	865.88	873.43	815.21	2,501.96	2,236.77	3,084.51
	f) Other expenses	4,995.13	5,972.71	4,271.75	14,366.79	12,460.41	17,129.15
	<b>Total Expenses</b>	<b>16,230.45</b>	<b>17,427.83</b>	<b>13,470.46</b>	<b>44,766.36</b>	<b>39,383.05</b>	<b>53,010.76</b>
3	<b>Profit before exceptional item and tax (1) - (2)</b>	<b>6,448.85</b>	<b>7,009.40</b>	<b>3,999.00</b>	<b>13,665.30</b>	<b>11,191.81</b>	<b>16,451.74</b>
4	<b>Exceptional items (refer note 3)</b>	-	-	-	-	686.48	2,452.66
5	<b>Profit before tax (3) - (4)</b>	<b>6,448.85</b>	<b>7,009.40</b>	<b>3,999.00</b>	<b>13,665.30</b>	<b>10,505.33</b>	<b>13,999.08</b>
6	<b>Tax expenses</b>						
	Current tax	1,147.00	2,043.00	846.10	3,387.00	2,283.30	3,933.00
	Deferred tax (income)/expense	493.62	(267.92)	(76.94)	75.35	(7.50)	(909.62)
	Tax adjustments for earlier years	(61.38)	(2.03)	-	(122.12)	-	(229.73)
	<b>Total tax expenses</b>	<b>1,579.24</b>	<b>1,773.05</b>	<b>769.16</b>	<b>3,340.23</b>	<b>2,275.80</b>	<b>2,793.65</b>
7	<b>Profit for the period / year (5) - (6)</b>	<b>4,869.61</b>	<b>5,236.35</b>	<b>3,229.84</b>	<b>10,325.07</b>	<b>8,229.53</b>	<b>11,205.43</b>
8	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(23.96)	(10.19)	(5.44)	(71.88)	(114.04)	(150.91)
	Items that will be subsequently reclassified to profit and loss (net of tax)	-	-	-	-	-	-
	<b>Other comprehensive (loss) / income for the period / year (net of tax)</b>	<b>(23.96)</b>	<b>(10.19)</b>	<b>(5.44)</b>	<b>(71.88)</b>	<b>(114.04)</b>	<b>(150.91)</b>
9	<b>Total comprehensive income (7) + (8)</b>	<b>4,845.65</b>	<b>5,226.16</b>	<b>3,224.40</b>	<b>10,253.19</b>	<b>8,115.49</b>	<b>11,054.52</b>
10	Paid-up equity share capital (face value - Rs. 2 per share)	1,022.13	1,018.57	1,003.57	1,022.13	1,003.57	1,012.61
11	Other equity						50,225.85
12	Earnings per share (of Rs.2 each) basic - (Rs.)*	9.56	11.52	6.44	20.31	16.40	22.32
	Earnings per share (of Rs.2 each) diluted - (Rs.)*	9.53	11.44	6.42	20.21	16.37	22.22

(\*not annualised)

See accompanying notes to the unaudited standalone financial results

**NOTES:**

- 1 These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The standalone financial results of the Company have been reviewed by the Audit Committee at their meeting held on 10 February 2021 and thereafter approved by the Board of Directors at their meeting held on 10 February 2021. The statutory auditors have expressed unqualified review opinion.
- 3 Exceptional items comprises of :
 

Particulars	For the quarter ended 31 December 2020	For the quarter ended 30 September 2020	For the quarter ended 31 December 2019	For nine months ended 31 December 2020	For nine months ended 31 December 2019	For the year ended 31 March 2020
Provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS)	-	-	-	-	336.48	336.48
Provision on account of certain old unreconciled balances	-	-	-	-	350.00	350.00
Provision on account of disputed trade receivables	-	-	-	-	-	1,766.18
<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>686.48</b>	<b>2,452.66</b>
- 4 Disclosure of segment –wise information is not applicable, as pathology services is the Company only business segment.
- 5 The Nomination and Remuneration Committee of the Board of Directors of the Company have on 11 November 2020 approved grant of 22,750 Restricted Stock Units (RSU) pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company, this is in addition to the RSU's approved under Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / Subsidiaries in the previous quarters.
- 6 On 5 November 2020, the Company has successfully acquired the balance stake of 49% in Raj Metropolis Healthcare Private Limited. Thus Raj Metropolis Healthcare Pvt Ltd. has now become a wholly-owned subsidiary of the Company.
- 7 On 17 January 2021, the Board of Directors of the Company approved acquisition of 100% stake in Dr Ganeshan's Hitech Diagnostic Center Private Limited and its subsidiary from its existing promoters / shareholders for a cash consideration of an amount of Rs 51,100 Lakhs and issuance of upto 4,95,000 equity share of the Company at a price which shall be determined on the relevant date pursuant to the provisions of the Regulation 164 of SEBI.
- 8 The Board of Directors of the Company has approved interim dividend of Rs 8 per equity share (face value of Rs 2 each) at the meeting held on 10 February 2021.
- 9 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 10 The results of the Company are available for investors at [www.metropolisindia.com](http://www.metropolisindia.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

Metropolis Healthcare Limited

Dr. Jushil Shah  
Chairman & Executive Director  
DIN: 00179918  
Place: Panchgani  
Date: 10 February 2021

# B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,  
Nesco IT Park 4, Nesco Center,  
Western Express Highway,  
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000  
Fax: +91 22 6257 1010

## **Limited review report on unaudited quarterly and year-to-date consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

### **To the Board of Directors of Metropolis Healthcare Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss of its joint venture for the quarter ended 31 December 2020 and year to date results for the period 1 April 2020 to 31 December 2020 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

**Limited review report on unaudited quarterly and year-to-date consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015  
(Continued)**

4. The Statement includes the results of the following entities:

<b>Sr No</b>	<b>Name of Entity</b>	<b>Relationship</b>
1	Sudharma Metropolis Health Services Private Limited	Subsidiary
2	Bokil Golwilkar Metropolis Healthcare Private Limited	Subsidiary
3	Raj Metropolis Healthcare Private Limited	Subsidiary
4	Desai Metropolis Health Services Private Limited	Subsidiary
5	R.V. Metropolis Diagnostics & Healthcare Centre Private Limited	Subsidiary
6	Micron Metropolis Healthcare Private Limited	Subsidiary
7	Dr. Patel Metropolis Healthcare Private Limited	Subsidiary
8	Lab One Metropolis Healthcare Services Private Limited	Subsidiary
9	Amins Pathology Laboratory Private Limited	Subsidiary
10	Ekopath Metropolis Lab Services Private Limited	Subsidiary
11	Metropolis Healthcare Lanka Private Limited	Subsidiary
12	Metropolis Healthcare (Mauritius) Limited	Subsidiary
13	Metropolis Star Lab Kenya Limited	Subsidiary
14	Metropolis Healthcare Ghana Limited	Subsidiary
15	Metropolis Bramser Lab Services (Mtius) Limited	Subsidiary
16	Metropolis Healthcare (Tanzania) Limited	Subsidiary
17	Metropolis Histoxpert Digital Services Private Limited	Joint Venture

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Limited review report on unaudited quarterly and year-to-date consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015  
(Continued)**

6. The Statement includes interim financial information of six (6) subsidiaries, which have not been reviewed, whose interim financial information reflects total revenue of Rs 997.15 lakhs and Rs 2,644.89 lakhs, total net profit after tax of Rs 122.72 lakhs and Rs 5.98 lakhs and total comprehensive income of Rs 103.73 lakhs and Rs 172.56 lakhs for the quarter ended 31 December 2020 and for the period from 1 April 2020 to 31 December 2020, respectively, as considered in the Statement. These financial information have been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on such management certified financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

**For B S R & Co. LLP**  
*Chartered Accountants*

Firm's Registration No: 101248W/W-100022

**TARUN K**  
**KINGER** Digitally signed by  
TARUN K KINGER  
Date: 2021.02.10  
14:38:51 +05'30'

**Tarun Kinger**  
*Partner*

Mumbai  
10 February 2021

Membership No: 105003  
ICAI UDIN: 21105003AAAAAP9120



**Metropolis Healthcare Limited**

Registered and Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400030

CIN:L73100MH2000PLC192798

Tel. No.: 022 6258 2810

Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070



**Statement of Consolidated Financial Results for the quarter and nine month ended 31 December, 2020**

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine month ended		Year ended
		31 December 2020	30 September 2020	31 December 2019	31 December 2020 (Unaudited)	31 December 2019 (Unaudited)	31 March 2020 (Audited)
1	<b>Income</b>						
	a) Revenue from operations	27,477.70	28,835.05	22,285.38	70,625.59	64,943.09	85,640.54
	b) Other income	374.14	308.47	218.95	998.01	549.54	856.66
	<b>Total Income</b>	<b>27,851.84</b>	<b>29,143.52</b>	<b>22,504.33</b>	<b>71,623.60</b>	<b>65,492.63</b>	<b>86,497.20</b>
2	<b>Expenses</b>						
	a) Cost of material consumed	6,933.99	7,444.94	5,232.36	18,194.14	15,319.20	20,413.50
	b) Laboratory testing charges	92.02	91.71	123.19	383.27	429.38	688.99
	c) Employee benefits expense	5,293.24	4,855.90	4,841.33	14,756.58	14,523.57	19,015.62
	d) Finance costs	164.86	154.14	239.58	506.07	606.73	834.47
	e) Depreciation and amortisation expense	1,097.01	1,101.40	1,055.91	3,186.18	2,812.30	3,926.72
	f) Other expenses	6,494.08	7,356.46	5,732.07	18,330.38	16,528.46	22,239.95
	<b>Total Expenses</b>	<b>20,075.20</b>	<b>21,004.55</b>	<b>17,224.44</b>	<b>55,356.62</b>	<b>50,219.64</b>	<b>67,119.25</b>
3	<b>Profit before exceptional items, share of profit for equity accounted investees and tax (1) - (2)</b>	<b>7,776.64</b>	<b>8,138.97</b>	<b>5,279.89</b>	<b>16,266.98</b>	<b>15,272.99</b>	<b>19,377.95</b>
4	<b>Exceptional Items (refer note 4)</b>	-	-	-	-	686.48	2,452.66
5	<b>Profit before share of profit for equity accounted investees and tax (3) - (4)</b>	<b>7,776.64</b>	<b>8,138.97</b>	<b>5,279.89</b>	<b>16,266.98</b>	<b>14,586.51</b>	<b>16,925.29</b>
6	<b>Share of loss for equity accounted investees (net of tax)</b>	-	-	-	-	(51.98)	(51.98)
7	<b>Profit before tax (5) + (6)</b>	<b>7,776.64</b>	<b>8,138.97</b>	<b>5,279.89</b>	<b>16,266.98</b>	<b>14,534.53</b>	<b>16,873.31</b>
8	<b>Tax expenses</b>						
	Current tax	1,315.31	2,361.77	1,173.52	3,964.15	3,371.84	5,326.98
	Deferred tax (income) /expense	659.19	(265.34)	(95.02)	233.39	(43.19)	(919.33)
	Tax adjustments for earlier years	(61.38)	(8.99)	-	(133.49)	-	(289.56)
	<b>Total tax expenses</b>	<b>1,913.12</b>	<b>2,087.44</b>	<b>1,078.50</b>	<b>4,064.05</b>	<b>3,328.65</b>	<b>4,118.09</b>
9	<b>Profit for the period/year (7) - (8)</b>	<b>5,863.52</b>	<b>6,051.53</b>	<b>4,201.39</b>	<b>12,202.93</b>	<b>11,205.88</b>	<b>12,755.22</b>
10	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(29.05)	(6.33)	(8.26)	(87.39)	(173.51)	(208.04)
	Items that will be subsequently reclassified to profit and loss (net of tax)	(16.13)	40.05	8.11	158.39	0.56	(92.11)
	<b>Other comprehensive income / (loss) for the period /year (net of tax)</b>	<b>(45.18)</b>	<b>33.72</b>	<b>(0.15)</b>	<b>71.00</b>	<b>(172.95)</b>	<b>(300.15)</b>
11	<b>Total comprehensive income (9) + (10)</b>	<b>5,818.34</b>	<b>6,085.25</b>	<b>4,201.24</b>	<b>12,273.93</b>	<b>11,032.93</b>	<b>12,455.07</b>
12	<b>Profit/ (loss) attributable to:</b>						
	Owners of the Company	5,856.94	6,027.88	4,207.22	12,174.87	11,183.27	12,732.56
	Non-controlling interest	6.58	23.65	(5.83)	28.06	22.61	22.66
13	<b>Other comprehensive income / (loss) attributable to:</b>						
	Owners of the Company	(45.93)	32.39	(0.14)	68.91	(172.62)	(300.18)
	Non-controlling interest	0.75	1.33	(0.01)	2.09	(0.33)	0.03
14	<b>Total comprehensive income / (loss) attributable to:</b>						
	Owners of the Company	5,811.01	6,060.27	4,207.08	12,243.78	11,010.65	12,432.37
	Non-controlling interest	7.33	24.98	(5.84)	30.15	22.28	22.70
15	<b>Paid-up equity share capital (face value - Rs. 2 per share)</b>	<b>1,022.13</b>	<b>1,018.57</b>	<b>1,003.57</b>	<b>1,022.13</b>	<b>1,003.57</b>	<b>1,012.61</b>
16	<b>Other equity (including Non-controlling interest)</b>						<b>51,502.76</b>
17	<b>Earnings per share (Face value of Rs.2 each) basic- (Rs.)*</b>	<b>11.50</b>	<b>11.88</b>	<b>8.38</b>	<b>23.95</b>	<b>22.29</b>	<b>25.36</b>
	<b>Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*</b>	<b>11.46</b>	<b>11.80</b>	<b>8.37</b>	<b>23.83</b>	<b>22.24</b>	<b>25.25</b>

(\*not annualised)

See accompanying note to the unaudited consolidated financial results



**NOTES:**

These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.

The above unaudited results were reviewed by the Audit Committee at their meeting held on 10 February 2021 and thereafter approved by the Board of Directors at their meeting held on 10 February 2021. The statutory auditors have expressed unqualified review opinion.

Metropolis Healthcare Limited (the 'Company' or the 'Parent'), and its subsidiaries (referred to collectively as the 'Group') and its joint venture are primarily involved in providing pathology and related healthcare services

Exceptional items comprises of : (in Rs Lakhs)

Particulars	For the quarter ended 31 December 2020	For the quarter ended 30 September 2020	For the quarter ended 31 December 2019	For nine Months ended 31 December 2020	For nine months ended 31 December 2019	For the year ended 31 March 2020
Provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS)	-	-	-	-	336.48	336.48
Provision on account of certain old unreconciled balances	-	-	-	-	350.00	350.00
Provision on account of disputed trade receivables	-	-	-	-	-	1,766.18
<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>686.48</b>	<b>2,452.66</b>

Disclosure of segment –wise information is not applicable, as pathology services is the Group's only business segment.

The Nomination and Remuneration Committee of the Board of Directors of the Company have on 11 November 2020 approved grant of 22,750 Restricted Stock Units (RSU) pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company, this is in addition to the RSUs approved under Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / Subsidiaries in the previous quarters.

On 17 January 2021, the Board of Directors of the Company approved acquisition of 100% stake in Dr Ganeshan's Hitech Diagnostic Center Private Limited and its subsidiary from its existing promoters / shareholders for a cash consideration of an amount of Rs 51,100 Lakhs and issuance of upto 4,95,000 equity share of the Company at a price which shall be determined on the relevant date pursuant to the provisions of the Regulation 164 of SEBI.

On 5 November 2020, the Company has successfully acquired the balance stake of 49% in Raj Metropolis Healthcare Private Limited. Thus Raj Metropolis Healthcare Pvt Ltd. has now become a wholly-owned subsidiary of the Company.

The Board of Directors of the Company have approved interim dividend of Rs 8 per equity share (face value of Rs 2 each) at the meeting held on 10 February 2021

The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

The results of the Company are available for investors at [www.metropolisindia.com](http://www.metropolisindia.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Metropolis Healthcare Limited

Dr. Sushil Shah  
Chairman & Executive Director  
DIN:00179918

Place: Panchgani  
Date: 10 February 2021

**Annexure – 2 : Details of Director being re-appointed**

<b>Name of Director</b>	Ms. Ameera Sushil Shah
<b>DIN</b>	00208095
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Re-appointment of Ms. Ameera Sushil Shah as the Managing Director of the Company for a further period of five years with effect from March 18, 2021, subject to the approval of the members of the Company at the ensuing General Meeting.
<b>Date of appointment / cessation (as applicable) and terms of appointment</b>	With effect from March 18, 2021, for a period of five years, subject to the approval of the members of the Company.
<b>Brief Profile</b>	<p>Ms. Ameera Sushil Shah, is the Promoter &amp; Managing Director of the Company. She has been associated with the Company as a Director on the Board, since 2008.</p> <p>She holds degree in Finance from The University of Texas at Austin and the prestigious Owner of President Management Program at Harvard Business School.</p> <p>For the last 20 years, she has focused on delivering sustained growth, built and led corporate functions of the Company, including finance, strategy, business process optimization, innovation and investor relations etc.</p> <p>Under her leadership, Metropolis raised the bar of diagnostic accuracy, technological equipment, customer experience, and research-driven, empathetic service.</p> <p>She was named amongst 'Asia's Most Powerful Women in Business' by Forbes Asia and 'Fifty Most Powerful Women in Business' by Fortune India. She is recognized as a global thought leader in the healthcare industry. She has also played an instrumental role in changing the pathology industry landscape in the country; from being a doctor led practice to a professional corporate group in an extremely unregulated, competitive and fragmented market.</p>
<b>Disclosure of relationship between Directors</b>	Ms. Ameera Sushil Shah is the daughter of Dr. Sushil Kanubhai Shah, the Chairman and Executive Director of the Company.
<b>Information as required pursuant to BSE Circular with ref. no. LIST / COMP/14/2018-2019 and the National Stock Exchange of India Ltd. with ref. no. NSE/CML/2018/24, dated 20th June, 2018</b>	Ms. Ameera Sushil Shah is not debarred from holding the office of the director by virtue of any SEBI order or any other such authority.

**BLOOD TESTS • DIAGNOSTICS • WELLNESS****Metropolis Healthcare Limited**

**Registered & Corporate Office:** 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.  
**CIN:** L73100MH2000PLC192798 **Tel No.:** 8422 801 801 **Email:** [support@metropolisindia.com](mailto:support@metropolisindia.com)  
**Website:** [www.metropolisindia.com](http://www.metropolisindia.com)  
**Global Reference Laboratory:** 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

**Annexure – 3 : Revised constitution of the Nomination and Remuneration Committee**

<b>Present Composition up to February 10, 2021</b>	<b>Revised Composition with effect from February 10, 2021</b>
1. Mr. Vivek Gambhir – Chairman	1. Ms. Anita Ramachandran – Chairperson
2. Ms. Anita Ramachandran – Member	2. Mr. Vivek Gambhir - Member
3. Mr. Sanjay Bhatnagar – Member	3. Mr. Sanjay Bhatnagar - Member

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**



**Metropolis Healthcare Limited**

**Registered & Corporate Office:** 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

**CIN:** L73100MH2000PLC192798 **Tel No.:** 8422 801 801 **Email:** [support@metropolisindia.com](mailto:support@metropolisindia.com)

**Website:** [www.metropolisindia.com](http://www.metropolisindia.com)

**Global Reference Laboratory:** 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.